摘要：New Zealand's health (and disability) ethics committees are children of public inquiries: the ‘Cartwright’ ministerial inquiry of 1988, the ‘Gisborne’ cervical screening ministerial inquiry of 2001, and the Health Select Committee clinical trials inquiry of 2011. The Cartwright inquiry strengthened external scrutiny of research. The Gisborne Inquiry strengthened ethics committee accountability and expertise, and greatly streamlined review process. The Health Select Committee inquiry is further sharpening accountability and process. Under-discussed systemic issues also persist, including: how to keep the ethical primacy of the researcher-participant relationship and of researcher responsibility for good study conduct; whether the point of ethics committees is to facilitate good research as well as to protect participants; and whether ethics committees are just standard public bodies - to be given powers and limitations just like any other administrative tribunal or licensing board.
